Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enveric Biosciences, Inc.AMRH · Entity 8193 | Director | January 24, 2017 | January 26, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enveric Biosciences, Inc.
Report date January 24, 2017 · Filed January 26, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,370 |
Reported balance
After 2017-01-24 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2017-01-24 · Exercise / conversion · Acquired 14,245 · Balance 69,370 F1: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | Direct | 55,125 |
Reported balance
Holding disclosure · report date 2017-01-24 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 55,125 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-01-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-24 · Exercise / conversion · Acquired 14,245 · Balance 0 F1: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person.
F2: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 24, 2017 Filed Jan 26, 2017 21:24 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionRestricted Stock Unit · Derivative | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-000105 · form410211002d_01262017.xml · derivative · entry 3 Rosenberg Robert Alan · CIK 0001643686 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,245 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · security: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.exercise_price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_price: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.exercise_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_date: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.expiration_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.expiration_date: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 21:24 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 14,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-17-000105 · form410211002d_01262017.xml · nonDerivative · entry 2 Rosenberg Robert Alan · CIK 0001643686 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · price: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.